These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31632612)

  • 1. U.S. Opioid Epidemic: Impact on Public Health and Review of Prescription Drug Monitoring Programs (PDMPs).
    Boté SH
    Online J Public Health Inform; 2019; 11(2):e18. PubMed ID: 31632612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
    Brown WC; Whitted K
    J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
    Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
    Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
    Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
    Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Implementation and Enforcement Differences in Prescription Drug Monitoring Programs in 3 States: Connecticut, Kentucky, and Wisconsin.
    Dickson-Gomez J; Christenson E; Weeks M; Galletly C; Wogen J; Spector A; McDonald M; Ohlrich J
    Subst Abuse; 2021; 15():1178221821992349. PubMed ID: 33854323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences.
    Kim B
    J Health Econ; 2021 Jan; 75():102408. PubMed ID: 33316762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use.
    Richwine C; Everson J
    J Gen Intern Med; 2023 Mar; 38(4):881-888. PubMed ID: 36229762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the impact of prescription drug monitoring program implementation: a scoping review.
    Finley EP; Garcia A; Rosen K; McGeary D; Pugh MJ; Potter JS
    BMC Health Serv Res; 2017 Jun; 17(1):420. PubMed ID: 28633638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?
    Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF
    Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prescription drug monitoring program in a multifactorial approach to the opioid crisis: PDMP data, Pennsylvania, 2016-2020.
    Adalbert JR; Syal A; Varshney K; George B; Hom J; Ilyas AM
    BMC Health Serv Res; 2023 Apr; 23(1):364. PubMed ID: 37046254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-level factors associated with implementation of prescription drug monitoring program integration and mandatory use policies, United States, 2009-2020.
    Johnson CE; Chrischilles EA; Arndt S; Carnahan RM
    J Am Med Inform Assoc; 2024 Oct; 31(10):2337-2346. PubMed ID: 38905012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: Evidence from the National Survey of Drug Use and Health.
    Ali MM; Dowd WN; Classen T; Mutter R; Novak SP
    Addict Behav; 2017 Jun; 69():65-77. PubMed ID: 28152391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis.
    Picco L; Lam T; Haines S; Nielsen S
    Drug Alcohol Depend; 2021 Nov; 228():109090. PubMed ID: 34600255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a Statewide Mandatory Prescription Drug Monitoring Program on Opioid Prescribing by Emergency Medicine Providers Across 15 Hospitals in a Single Health System.
    Suffoletto B; Lynch M; Pacella CB; Yealy DM; Callaway CW
    J Pain; 2018 Apr; 19(4):430-438. PubMed ID: 29241835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
    Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
    J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do prescription drug monitoring programs encourage prescription - or illicit - opioid abuse?
    Meadowcroft D; Whitacre B
    Subst Abus; 2021; 42(1):65-75. PubMed ID: 31821128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.